Established in 2004, this vertically integrated pharmaceutical manufacturer is committed to delivering high-quality, affordable medicines globally. As a CTD dossier owner and manufacturer, it holds GMP certifications from the US FDA, EU, and WHO, ensuring compliance with stringent international quality standards. The company's state-of-the-art R&D center is capable of handling oral solids, liquids, and parenteral formulations. Its products have received marketing authorizations from regulatory authorities such as the US FDA, Health Canada, CDSCO-India, and New Zealand. With over 20 ANDA/ANDs under approval, the manufacturer operates advanced production lines adhering to rigorous GMP guidelines. Its diverse portfolio includes therapeutics in areas like antivirals, neurology, women's health, cardiology, and imaging contrast agents.

The CTD dossier owner and manufacturer is a leading conglomerate with a diverse range of business operations across multiple industries. The website is structured to provide detailed financial information through sections like “Annual Report,” “Quarterly Report,” and “Price Sensitive Information,” which include links to various reports from recent years and updates on financial performance, such as notices about bond issuances. The company operates in several key sectors, including textiles, pharmaceuticals, personal protective equipment (PPE), ceramics, information and communication technology (ICT), real estate and trading, media, financial services, energy, and travel and tourism. As the largest entity within its group, the company plays a significant role in driving economic activities and growth across these industries, reflecting its strong market presence and commitment to diversified business interests.